Factor 8 Ehl denied as not FDA-approved for this use by UnitedHealthcare?

UnitedHealthcare's specific coverage criteria for factor 8 ehl are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why UnitedHealthcare Denied Your Extended Half-Life Factor VIII — "Not FDA-Approved"

Extended half-life (EHL) Factor VIII products are a class of recombinant clotting factor concentrates engineered to remain active in the bloodstream longer than standard Factor VIII, reducing the frequency of infusions for people with hemophilia A. Several EHL Factor VIII products have received FDA approval, and this class is recognized by major hemophilia treatment guidelines. A denial coded "not FDA-approved" almost always means UHC's system did not match the specific product National Drug Code (NDC) on the claim to an entry on its coverage list — not that the product lacks FDA clearance. This is a correctable administrative error and is highly appealable.

## Why This Denial Is Appealable

If your prescriber ordered an FDA-approved EHL Factor VIII product, the "not FDA-approved" rationale is factually incorrect on its face. Before appealing, confirm with your specialty pharmacy that the NDC billed corresponds to an FDA-approved product and that the correct drug name and HCPCS/procedure code were submitted. A single coding mismatch can trigger an automatic denial that has nothing to do with the drug's approval status.

## Federal Appeal Framework

• Internal appeal (Level 1): File with UHC within 180 days of the denial notice. UHC must decide urgent/expedited appeals within 72 hours and standard appeals within 30 days for pre-service or 60 days for post-service claims.
• External review (Level 2): If UHC upholds the denial, you have the right to an independent external review under ACA §2719. You generally have four months from the final internal denial to request external review. An independent review organization — not UHC — decides.
• Expedited option: If a delay would seriously jeopardize your health (e.g., active bleeding, upcoming surgery), request expedited internal and expedited external review simultaneously.
• ERISA plans: If your coverage is employer-sponsored, ERISA §503 guarantees a full-and-fair review with access to the specific criteria used to deny the claim.

## Documentation to Gather

1. FDA approval confirmation — print the FDA product label or the FDA Orange Book entry showing the exact product name and approval date. 2. Pharmacy claim documentation — the NDC, drug name, HCPCS code, and quantity as actually submitted. 3. Prescriber letter — a brief statement confirming the ordered product is FDA-approved and medically necessary for this patient's confirmed hemophilia A diagnosis. 4. Diagnosis records — lab documentation of Factor VIII deficiency and hemophilia A severity classification from your hematologist or hemophilia treatment center (HTC).

## Criteria-Mapping Structure

In your appeal letter, create a table with two columns: - Column A: Each requirement stated in UHC's denial letter or its published medical/coverage policy for this drug class. - Column B: The specific chart fact, lab result, or document that satisfies that requirement.

For an FDA-approval denial, Column A should include the exact approval-status language from UHC's policy, and Column B should cite the FDA label page, approval date, and NDC match. Attach the supporting documents as labeled exhibits referenced in the letter.